Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Good financial results growth rate 19.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-10.0%)
  • Dividend yield for the last twelve months 3.5%
  • Free cash flow yield -2.7% (LTM)
  • Share price is 37.6% higher than minimum and 15.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (35.8x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $12.4 mln (-0.003% of cap.)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (-2.4%)182.31
year average price 187.31  


year start price 171.52 2024-06-30

min close price 164.11 2024-07-03

max close price 216.66 2025-03-10

current price 182.31 2025-06-29
Common stocks: 1 768 480 508

Dividend Yield:  3.5%
FCF Yield LTM: -2.7%
EV / LTM EBITDA: 35.8x
EV / EBITDA annualized: 24.7x
Last revenue growth (y/y):  +8.4%
Last growth of EBITDA (y/y):  +31.3%
Historical revenue growth:  +0.5%
Historical growth of EBITDA:  -20.4%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 322 412
Net Debt ($m): 64 755
EV (Enterprise Value): 387 167
EBITDA LTM ($m): 10 815
EV / LTM EBITDA: 35.8x
Price to Book: 53.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-29seekingalpha.com

Best Dividend Aristocrats For July 2025

2025-06-29fool.com

3 Dividend Stocks to Double Up on Right Now

2025-06-28fool.com

Got $500? 2 Healthcare Stocks to Buy and Hold Forever

2025-06-27zacks.com

AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock

2025-06-26247wallst.com

Jim Cramer's Safest Stock For Retirees

2025-06-23invezz.com

3 dividend stocks investors can look for stability as Iran attacks US base in Qatar

2025-06-18prnewswire.com

AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention

2025-06-17zacks.com

Here's Why AbbVie (ABBV) Fell More Than Broader Market

2025-06-17zacks.com

AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study

2025-06-17seekingalpha.com

AbbVie's Diversification Strategy Cushions Venetoclax MDS Blow
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data